• Molecular NamePalonosetron
  • Synonympalonosetron
  • Weight296.414
  • Drugbank_IDDB00377
  • ACS_NO135729-61-2
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.1
  • pkaN/A
  • LogD (pH=7, predicted)0.7
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.16
  • LogSw (predicted, AB/LogsW2.0)0.2
  • Sw (mg/ml) (predicted, ACD/Labs)0.17
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds1
  • TPSA23.55
  • StatusFDA approved
  • AdministrationIntravenous, oral
  • PharmacologyA 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability97.0
  • Protein binding62.0
  • Volume of distribution (VD)5.9~11 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, 50% (mostly CYP2D6-mediated, CYP3A4 and CYP1A2 also involved)
  • Half life40 h
  • ExcretionRenal, 80% (of which 49% unchanged); fecal (5 to 8%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A